AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
Stopped This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.
Conditions
- Nonalcoholic Steatohepatitis
Interventions
- DRUG: Placebo
- DRUG: Cenicriviroc
Sponsor
Tobira Therapeutics, Inc.